Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at risk who remain on NSAIDs.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. For maintenance, 40 mg orally once daily.
* **NSAID-Associated Gastric Ulcers:** 40 mg orally once daily for up to 8 weeks.
* **H. pylori Eradication (in combination therapy):** 40 mg orally twice daily for 7-14 days with antibiotics.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg orally twice daily; titrate as needed. Doses up to 240 mg orally once daily and 120 mg IV every 8 hours have been used.
* **IV Dosing (for patients unable to take oral medication):** 40 mg IV once daily. For pathological hypersecretory conditions, doses up to 80 mg IV every 8 hours may be used.
## Pediatric Dosing
* **Erosive Esophagitis (GERD-associated):**
* **1-5 years:** 10 mg orally once daily for up to 8 weeks.
* **6-11 years:** 20 mg orally once daily for up to 8 weeks.
* **12-17 years:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing (GERD-associated):**
* **1-11 years:** 20 mg orally once daily.
* **12-17 years:** 40 mg orally once daily.
*Note: Pediatric IV dosing is not well established and should be based on institutional protocols.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose is 40 mg orally once daily.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Long-term use (associated with increased risk of):**
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Hypomagnesemia
* Vitamin B12 deficiency
* Fundic gland polyps
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, POSACONAZOLE, ERYTHROMYCIN, MYCOPHENOLATE MOFETIL, diazepam, phenytoin, warfarin. Consider alternative therapies or dose adjustments.
* **Methotrexate:** PPIs may increase methotrexate levels. Consider holding PPI during methotrexate therapy.
* **Rilpivirine, Atazanavir:** Avoid concomitant use as pantoprazole can decrease their absorption.
* **Voriconazole:** May increase pantoprazole levels.
## Monitoring
* Electrolytes (especially magnesium) with prolonged therapy or concurrent diuretic use.
* Bone density screening for patients at risk of osteoporosis with long-term therapy.
* Clinical signs and symptoms of C. difficile infection.
* For patients on warfarin, monitor INR closely.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* For IV administration, reconstitute and infuse as per manufacturer's instructions. Do not infuse with other medications.
* Long-term use of PPIs should be re-evaluated regularly.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines before making treatment decisions.*
